Moreover, the combination therapy of gefitinib and durvalumab in advanced NSCLC patients with EGFR-sensitive mutations (19 deletions and 21 L858R) showed grade 3 or 4 elevated levels of AST (70% in arm 1, 60% in arm 2) and ALT (40% in arm 1, 50% in arm 2), but both events could be controlled after the drug withdrawal or administration of corticosteroids (Gibbons et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.